Associated Genetic Biomarkers
GRB2 is altered in 0.00% of all cancers with invasive breast carcinoma having the greatest prevalence of alterations .
The most common alteration in GRB2 is GRB2-SOX9 Fusion (0.00%) .
GRB2 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain GRB2 status as an inclusion criterion, 2 are phase 2 (1 open).
Trials with GRB2 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are GRB2 Amplification, GRB2 Mutation, and GRB2 Overexpression .
Capmatinib and gefitinib are the most frequent therapies in trials with GRB2 as an inclusion criteria .
Significance of GRB2 in Diseases
Hepatocellular Carcinoma +
GRB2 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GRB2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Non-Small Cell Lung Carcinoma +
GRB2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GRB2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.